PSA screening in New Zealand: Total population results and general practitioners' current attitudes and practices

New Zealand Medical Journal

Volumn 126, Issue 1381, 2013, Pages 27-36

  van Rij, Simon ^a   Dowell, Tony ^b   Nacey, John ^b  

^a WELLINGTON HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; GENERAL PRACTITIONER; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; INCIDENCE; MALE; MEASUREMENT ACCURACY; MEDICAL EXAMINATION; PHYSICIAN ATTITUDE; PROSTATE CANCER; QUESTIONNAIRE; SELF REPORT;

ADULT; AGED; AGED, 80 AND OVER; ATTITUDE OF HEALTH PERSONNEL; EARLY DETECTION OF CANCER; GENERAL PRACTITIONERS; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES;

EID: 84883287124     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ministry of Health. Age-specific rates per 100, 000 for the five most common causes of cancer death 2008. Wellington: Ministry of Health, 2011.
2. Pashayan N, Powles J, Brown C, Duffy SW. Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia. Br J Cancer. 2006;95(3):401-5.
3. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95(12):868-78
4. Schröder FH, et al. Prostate-cancer mortality at 11 years of follow-up, N Eng J Med, 2012;366: 981-990.
5. Center MM, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079-1092.
6. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101:1325-1329.
7. Balk PB, Ko YJ, Bubley GJ. Biology of prostate-specific antigen, JCO. 2003;21(2): 383-391.
8. "Inquiry into early detection and treatment of prostate cancer" Report of the Health Committee Forty-ninth Parliament (Dr Paul Hutchison, Chairperson). Presented to the House of Representatives. July 2011.
9. Ministry of Health. Diagnosis and management of prostate cancer in New Zealand men. Recommendations from the Prostate Cancer Taskforce, 2012.
10. Ministry of Health. Cancer: new registrations and deaths 2009. Wellington: Ministry of Health, 2012.
11. Williams N et al. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. BJU Int. 2011;108(9):1402-1408.
12. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA. 2003;289(11):1414-1420.
13. Tuppin P, et al. Prostate-specific antigen use among men without prostate cancer in France (2008-2010). Bulletin Du Cancer. 2012;99(5):521-7.
14. Smith DP, Supramaniam R, Marshall VR, et al. Prostate cancer and prostate-specific antigen testing in New South Wales. Med J Aus. 2008;189:315-8.
15. Center MM, et al. International variation in prostate cancer incidence and mortality rates. European Urology. 2012;61:1079-1092.
16. Durham J, Low M, McLeod D. Screening for prostate cancer: a survey of New Zealand general practitioners. N Z Med J. 2003;116(1176): U476.
17. Andriole GL, et al. Prostate cancer screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125-132.
18. National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).
19. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012 Jul 19;367(3):203-13.
20. Gormley GJ, et al. Prostate-specific antigen testing: uncovering primary care influences. BJU Int. 2006;98(5):996-1000.
21. Gattellari M, Young JM, Ward JE. GP and patient predictors of PSA screening in Australian general practice. Family Practice. 2003;20(3):294-303.
22. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012 Jul 17;157(2):I-44.